Key Details
Annual ROE
-61.95%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Aug 15, 2023Recent annual earnings:
Mar 30, 2022Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
June 02, 2023Analyst ratings
Recent major analysts updates
18 July '22 HC Wainwright & Co.
Neutral30 June '22 Stifel
Hold30 June '22 Oppenheimer
Perform23 May '22 HC Wainwright & Co.
Buy18 Apr '22 HC Wainwright & Co.
Buy10 Dec '21 Oppenheimer
Outperform09 Nov '21 HC Wainwright & Co.
Buy27 Oct '21 Stifel
Buy02 Mar '21 Stifel
Buy02 Mar '21 Oppenheimer
OutperformScreeners with ANGN included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Angion Biomedica doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
FAQ
- What is the primary business of Angion Biomedica?
- What is the ticker symbol for Angion Biomedica?
- Does Angion Biomedica pay dividends?
- What sector is Angion Biomedica in?
- What industry is Angion Biomedica in?
- What country is Angion Biomedica based in?
- When did Angion Biomedica go public?
- Is Angion Biomedica in the S&P 500?
- Is Angion Biomedica in the NASDAQ 100?
- Is Angion Biomedica in the Dow Jones?
- When was Angion Biomedica's last earnings report?
- When does Angion Biomedica report earnings?
- Should I buy Angion Biomedica stock now?
What is the primary business of Angion Biomedica?
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for chronic and progressive fibrotic diseases in the United States. The company develops ANG-3070, an oral tyrosine kinase receptor inhibitor for fibrotic diseases in kidney and lung. It also develops ROCK2 inhibitors for fibrotic diseases; CYP11B2, an inhibitor program for aldosterone-related diseases, including resistant hypertension, congestive heart failure, renal fibrosis, and hyperaldosteronism; and CYP26 for the degradation of retinoic acid. Angion Biomedica Corp. was incorporated in 1998 and is based in Uniondale, New York.
What is the ticker symbol for Angion Biomedica?
The ticker symbol for Angion Biomedica is NASDAQ:ANGN
Does Angion Biomedica pay dividends?
No, Angion Biomedica does not pay dividends
What sector is Angion Biomedica in?
Angion Biomedica is in the Healthcare sector
What industry is Angion Biomedica in?
Angion Biomedica is in the Biotechnology industry
What country is Angion Biomedica based in?
Angion Biomedica is headquartered in United States
When did Angion Biomedica go public?
Angion Biomedica's initial public offering (IPO) was on 05 February 2021
Is Angion Biomedica in the S&P 500?
No, Angion Biomedica is not included in the S&P 500 index
Is Angion Biomedica in the NASDAQ 100?
No, Angion Biomedica is not included in the NASDAQ 100 index
Is Angion Biomedica in the Dow Jones?
No, Angion Biomedica is not included in the Dow Jones index
When was Angion Biomedica's last earnings report?
Angion Biomedica's most recent earnings report was on 15 August 2023
When does Angion Biomedica report earnings?
The date for Angion Biomedica's next earnings report has not been announced yet
Should I buy Angion Biomedica stock now?
As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions